Condition: Colon Cancer · Rectal Cancer · Colorectal Cancer · Sponsor: SCRI Development Innovations, LLC
This is an open-label multicenter, single-arm Phase II study of Fruquintinib in combination with FOLFIRI (leucovorin calcium (folinic acid), fluorouracil, and irinotecan) in participants with metastatic colorectal cancer (mCRC). The main goals of this study are to: * Evaluate the efficacy of the combination of fruquintinib + FOLFIRI in the 2nd-line mCRC setting * Evaluate the safety of the combination of fruquintinib + FOLFIRI
This description comes directly from the study's public registry record.
Sarah Cannon Sarah Cannon Development Innovations, LLC · 844-710-6157 · SCRI.InnovationsMedical@scri.com
Always discuss trial participation with your own doctor first.
| Rocky Mountain Cancer Center - Primary | Denver, Colorado, United States | Recruiting |
| Illinois Cancer Specialists | Arlington Heights, Illinois, United States | Recruiting |
| Maryland Oncology Hematology | Columbia, Maryland, United States | Recruiting |
| Minnesota Oncology Hematology - Primary | Maple Grove, Minnesota, United States | Recruiting |
| Missouri Cancer Associates | Columbia, Missouri, United States | Recruiting |
| Oncology Associates of Oregon - Primary | Eugene, Oregon, United States | Recruiting |
| Northwest Cancer Specialists - Compass | Portland, Oregon, United States | Recruiting |
| Alliance Cancer Specialists | Wynnewood, Pennsylvania, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| Texas Oncology - Central/South Texas | Austin, Texas, United States | Recruiting |
| Texas Oncology - Gulf Coast | Beaumont, Texas, United States | Recruiting |
| Texas Oncology - Northeast Texas | Tyler, Texas, United States | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07011576